- Medicines and Healthcare products Regulatory Agency
- Part of:
- Patient safety
- 2 July 2014
- Last updated:
- 27 January 2015, see all updates
Detail of outcome
The Medicines and Healthcare products Regulatory Agency (MHRA) has agreed to reclassify Nexium Control from a pharmacy (P) medicine to a general sales list medicine (GSL) in the UK for the short-term treatment of reflux symptoms (eg heartburn and acid regurgitation) in adults.
See the public assessment report for more information.
Detail of feedback received
This consultation (ARM88) welcomes views on proposals to classify Nexium Control 20mg Gastro-Resistant Tablets as a general sales list (GSL) product in the UK.
This consultation ran from
MHRA is asking for feedback on proposals to classify Nexium Control 20mg Gastro-Resistant tablets as a general sales list (GSL) product in the UK. The GSL classification summary and label and patient information leaflet as provided by the company are included in this document.
Consultation document, ARM88 - Nexium Control 20mg Gastro-Resistant Tablets - request to classify as GSL
PDF, 3.5MB, 18 pages
This file may not be suitable for users of assistive technology. Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email email@example.com. Please tell us what format you need. It will help us if you say what assistive technology you use.
Published: 2 July 2014
Updated: 27 January 2015
- The responses to and outcome of this consultation have been published.
- First published.